Tiziana Life Sciences (LON:TILS) Shares Cross Below 200-Day Moving Average of $73.03

Tiziana Life Sciences PLC (LON:TILS)’s share price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 73.03 ($0.95) and traded as low as GBX 52 ($0.68). Tiziana Life Sciences shares last traded at GBX 52.50 ($0.69), with a volume of 214,556 shares.

The firm has a 50-day moving average of GBX 58.92 and a 200 day moving average of GBX 72.89. The stock has a market capitalization of £103.63 million and a price-to-earnings ratio of -3.25. The company has a current ratio of 6.54, a quick ratio of 6.41 and a debt-to-equity ratio of 2.36.

In related news, insider Gabriele Cerrone purchased 60,000 shares of Tiziana Life Sciences stock in a transaction that occurred on Monday, October 4th. The shares were purchased at an average cost of GBX 50 ($0.65) per share, with a total value of £30,000 ($39,195.19). Insiders have purchased a total of 197,500 shares of company stock worth $10,037,500 over the last three months.

About Tiziana Life Sciences (LON:TILS)

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma.

Further Reading: Cash Asset Ratio

Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.